文献速递银屑病与炎症性皮肤病

Bimekizumab治疗中国银屑病患者的BE SHINING III期研究

Bimekizumab efficacy and safety in Chinese patients with psoriasis in the BE SHINING Phase 3 study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2026-02-12

BE SHINING是一项针对中国中重度斑块状银屑病患者的III期随机对照研究,评估Bimekizumab的疗效与安全性。第16周时Bimekizumab组PASI 90和IGA 0/1应答率均显著高于安慰剂组,安全性与全球研究一致。

要点

  • Bimekizumab在第16周显著提高PASI 90和IGA 0/1应答率。
  • 第16周PASI 100应答率显著高于安慰剂。
  • 常见不良事件为轻中度,未发现新安全信号。

核心结论

  • Bimekizumab在中国中重度斑块状银屑病患者中耐受良好,临床应答率显著高于安慰剂,包括完全皮损清除,结果与全球研究一致。

研究设计与样本

  • BE SHINING为III期随机对照研究,患者按3:1随机接受Bimekizumab 320 mg Q4W至第16周后Q8W至第32周,或安慰剂Q4W至第16周后Bimekizumab Q4W至第32周。
  • 共随机133例患者(Bimekizumab Q4W/Q8W组N=100;安慰剂/Bimekizumab Q4W组N=33)。
  • 缺失数据按无应答处理,P值基于Cochran-Mantel-Haenszel检验。
  • 安全性在至少接受1剂治疗的患者中评估(第0-32周)。

主要发现

  • 第16周,Bimekizumab组PASI 90应答率为94.0% vs 安慰剂组3.0%,IGA 0/1应答率为92.0% vs 3.0%(均p<0.001)。
  • 第4周PASI 75应答率为74.0% vs 3.0%(p<0.001),第16周PASI 100应答率为65.0% vs 0.0%(p<0.001)。
  • 第32周时,Bimekizumab Q4W/Q8W组与安慰剂/Bimekizumab Q4W组的应答率相似。
  • 截至第32周,在至少接受1剂Bimekizumab的患者中,TEAE发生率为73.8%,严重TEAE为6.2%,导致停药的TEAE为5.4%。
  • 最常见TEAE为上呼吸道感染、肝功能异常和注射部位疼痛;未发现新安全信号。

关键数值与推荐

  • 主要终点:第16周达到PASI 90和IGA 0/1的患者比例。
  • 次要终点:第4周PASI 75和第16周PASI 100应答率。

临床怎么用

  • Bimekizumab可用于中国中重度斑块状银屑病患者,第16周可显著提高PASI 90和IGA 0/1应答率。
  • 治疗期间需关注上呼吸道感染、肝功能异常和注射部位疼痛等常见不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bimekizumab was well tolerated and demonstrated superior efficacy in global psoriasis studies; however, these included few Chinese patients. OBJECTIVES: To evaluate the efficacy and safety of bimekizumab in Chinese patients with moderate to severe plaque psoriasis. METHODS: In BE SHINING, patients were randomized 3:1 to bimekizumab 320 mg every 4 weeks (Q4W) to Week 16 then every 8 weeks (Q8W) to Week 32, or to placebo Q4W to Week 16 then bimekizumab Q4W to Week 32. Primary endpoints included achievement of ≥90% improvement from baseline in the Psoriasis Area and Severity Index (PASI 90) and Investigator's Global Assessment (IGA) of 0/1 at Week 16. Secondary endpoints included PASI 75/PASI 100 response rates at Week 4/16, respectively. Missing data were imputed as non-response; p values were based on the Cochran-Mantel-Haenszel test. Safety outcomes were assessed in patients who received ≥1 treatment dose (Weeks 0-32). RESULTS: Overall, 133 patients were randomized (bimekizumab Q4W/Q8W: N = 100; placebo/bimekizumab Q4W: N = 33). Bimekizumab-treated patients had significantly higher primary endpoint response rates versus placebo (Week 16; PASI 90: 94.0% vs. 3.0%; IGA 0/1: 92.0% vs. 3.0%; p < 0.001 for both), and significantly higher rates of PASI 75 (Week 4; 74.0% vs. 3.0%; p < 0.001) and PASI 100 (Week 16; 65.0% vs. 0.0%; p < 0.001). Response rates were similar in bimekizumab Q4W/Q8W and placebo/bimekizumab Q4W patients at Week 32. Through Week 32, in patients who received ≥1 bimekizumab dose, rates of treatment-emergent adverse events (TEAEs), serious TEAEs and TEAEs leading to discontinuation were 73.8%, 6.2% and 5.4%. The most common TEAEs were upper respiratory tract infection, hepatic function abnormal and injection site pain; no new safety signals were identified. CONCLUSIONS: Bimekizumab treatment was well tolerated and led to significantly higher clinical response rates versus placebo, including complete skin clearance, in Chinese patients with moderate to severe psoriasis. Findings were consistent with global studies. A study investigating how well bimekizumab works for treating psoriasis in Chinese people and what the side effects were. PSORIASIS IN CHINA: Psoriasis is a long‐lasting disease that causes red, scaly skin patches which flake, itch and hurt. Psoriasis affects relatively fewer people in China compared to Western countries. However, the number of Chinese people with psoriasis is growing and many have other health conditions alongside psoriasis, like liver and heart disease or Type 2 diabetes. Chinese people with psoriasis expect treatments to completely clear the skin and maintain clearance for longer. Finding new treatments that meet Chinese people’s treatment goals, with tolerable side effects, is important. WHAT DID WE DO?: Bimekizumab is a drug for psoriasis given by injection under the skin. Bimekizumab has shown beneficial results in global studies, but these did not include many Chinese people. In our study, called BE SHINING, we tested bimekizumab in Chinese people with moderate to severe psoriasis. People either took bimekizumab for 32 weeks, or they received an imitation medicine (placebo) for 16 weeks followed by bimekizumab for 16 weeks. WHAT DID WE FIND?: After 16 weeks of treatment, 94 out of 100 people who took bimekizumab achieved almost clear or clear skin, significantly more than people taking placebo (1 out of 33). After 32 weeks of bimekizumab treatment, a similar proportion of people continued to have clear or almost clear skin. The most common side effects were mild to moderate: nose/mouth/throat infections, abnormal liver function/tests and injection site pain. These results suggest that bimekizumab is an effective treatment option, with tolerable side effects, for Chinese people living with psoriasis. (A version of the Plain Language Summary in simplified Chinese can be found in the Supporting Information).

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Cai L, Man XY, Wang J, et al. Bimekizumab efficacy and safety in Chinese patients with psoriasis in the BE SHINING Phase 3 study. J Eur Acad Dermatol Venereol. 2026. PMID: 41678327. doi:10.1111/jdv.70350

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。